UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Neoadjuvant treatments for triple-negative breast cancer (TNBC)

Annals of oncology, 2012-08, Vol.23 Suppl 6, p.vi35-vi39

2012

Volltextzugriff (PDF)

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto

Annals of oncology, 2018-12, Vol.29 (12), p.2341-2347

2018

Volltextzugriff (PDF)

Neoadjuvante Systemtherapie beim Mammakarzinom

Gynäkologe (Berlin), 2012-06, Vol.45 (6), p.453-459

2012

Volltextzugriff (PDF)

Early prediction of pathologic response to neoadjuvant therapy in breast cancer: Systematic review of the accuracy of MRI

Breast (Edinburgh), 2012-10, Vol.21 (5), p.669-677

2012

Volltextzugriff (PDF)

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006

Annals of oncology, 2007-12, Vol.18 (12), p.1927-1934

2007

Volltextzugriff (PDF)

Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy

Annals of oncology, 2015-01, Vol.26 (1), p.95-100

2015

Volltextzugriff (PDF)

Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer

Breast cancer research and treatment, 2018-02, Vol.168 (1), p.179-187

2018

Volltextzugriff (PDF)

Translationale Forschung am Beispiel neoadjuvanter Mammakarzinom-Studien

Geburtshilfe und Frauenheilkunde, 2006, Vol.66 (9), p.827-832

von Minckwitz, G.

2006

Volltextzugriff (PDF)

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

Annals of oncology, 2019-08, Vol.30 (8), p.1279-1288

2019

Volltextzugriff (PDF)

Neoadjuvante Chemotherapie von Mammakarzinomen

Gynäkologe (Berlin), 2005-05, Vol.38 (5), p.398-407

von Minckwitz, G.

2005

Volltextzugriff (PDF)

BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial

Breast cancer research and treatment, 2017-12, Vol.166 (3), p.775-785

2017

Volltextzugriff (PDF)

Optimizing taxane use in MBC in the emerging era of targeted chemotherapy

Critical reviews in oncology/hematology, 2013-03, Vol.85 (3), p.315-331

2013

Volltextzugriff (PDF)

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

Annals of oncology, 2016-08, Vol.27 (8), p.1519-1525

2016

Volltextzugriff (PDF)

Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE

Annals of oncology, 2021-08, Vol.32 (8), p.1005-1014

2021

Volltextzugriff (PDF)

St.-Gallen-Konferenz 2009 zum primären Mammakarzinom

Geburtshilfe und Frauenheilkunde, 2009-05, Vol.69 (5), p.377-383

2009

Volltextzugriff (PDF)

Reply to Ki67 in breast cancer: a useful prognostic marker

Annals of oncology, 2014-02, Vol.25 (2), p.542-543

2014

Volltextzugriff (PDF)

Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial

Annals of oncology, 2017-03, Vol.28 (3), p.497-504

2017

Volltextzugriff (PDF)

Prognostische Bedeutung des Tumorzellnachweises im Knochenmark im Vergleich zum Nodalstatus beim primären Mammakarzinom

Geburtshilfe und Frauenheilkunde, 1997-06, Vol.57 (6), p.333-341

1997

Volltextzugriff (PDF)

Stadienadaptierte Therapie des Mammakarzinoms

Gynäkologe (Berlin), 2006-08, Vol.39 (8), p.618-626

2006

Volltextzugriff (PDF)

Methylation of estrogen receptor β promoter correlates with loss of ER-β expression in mammary carcinoma and is an early indication marker in premalignant lesions

Endocrine-related cancer, 2005-12, Vol.12 (4), p.903-916

2005

Volltextzugriff (PDF)

Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study

Annals of oncology, 2016-11, Vol.27 (11), p.2053-2059

2016

Volltextzugriff (PDF)

PG 8.03 Clinical usefulness and relevance of intermediate endpoints for cytotoxic primary systemic therapy

Breast (Edinburgh), 2015-03, Vol.24, p.S14-S15

Von Minckwitz, G

2015

Volltextzugriff (PDF)

St. Gallen Konsensus 2007 aus deutscher Sicht. Kommentare einer deutschen Arbeitsgruppe zur Therapie des primären Mammakarzinoms

Geburtshilfe und Frauenheilkunde, 2007-07, Vol.67 (7), p.774-778

2007

Volltextzugriff (PDF)

Comprehensive Review on the Surrogate Endpoints of Efficacy Proposed or Hypothesized in the Scientific Community Today

Journal of the National Cancer Institute. Monographs, 2015-05, Vol.2015 (51), p.29-31

2015

Volltextzugriff (PDF)

1 – 25 von 430

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Clinical Oncology

Zeitschrift / SerieOnkologie

ThemaMedical Sciences

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(388)
Mit Volltextzugriff
(336)

Publikationsform

Sprache

Englisch
(319)
Deutsch
(114)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(77)
Science & Technology
(74)
Life Sciences & Biomedicine
(73)
Female
(72)
Oncology
(60)
Breast Cancer
(41)
Breast Neoplasms - Drug Therapy
(41)
Hematology, Oncology And Palliative Medicine
(40)
Breast Neoplasms - Pathology
(35)
Middle Aged
(29)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(28)
Adult
(22)
Aged
(20)
Prognosis
(20)
Breast Neoplasms - Mortality
(19)
Chemotherapy, Adjuvant
(19)
Disease-Free Survival
(17)
Neoadjuvant Therapy
(15)
Obstetrics & Gynecology
(15)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(14)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Cancer Research
(109)
Annals Of Oncology
(58)
European Journal Of Cancer Supplements
(31)
European Journal Of Cancer
(21)
Geburtshilfe Und Frauenheilkunde
(20)
Zentralblatt Für Gynäkologie
(19)
Breast
(16)
Senologie
(14)
Anti-Cancer Drugs
(6)
Gynäkologe
(6)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Neoadjuvant treatments for triple-negative breast cancer (TNBC)

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto

Neoadjuvante Systemtherapie beim Mammakarzinom

Early prediction of pathologic response to neoadjuvant therapy in breast cancer: Systematic review of the accuracy of MRI

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006

Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy

Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer

Translationale Forschung am Beispiel neoadjuvanter Mammakarzinom-Studien

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

Neoadjuvante Chemotherapie von Mammakarzinomen

BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial

Optimizing taxane use in MBC in the emerging era of targeted chemotherapy

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE

St.-Gallen-Konferenz 2009 zum primären Mammakarzinom

Reply to Ki67 in breast cancer: a useful prognostic marker

Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial

Prognostische Bedeutung des Tumorzellnachweises im Knochenmark im Vergleich zum Nodalstatus beim primären Mammakarzinom

Stadienadaptierte Therapie des Mammakarzinoms

Methylation of estrogen receptor β promoter correlates with loss of ER-β expression in mammary carcinoma and is an early indication marker in premalignant lesions

Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study

PG 8.03 Clinical usefulness and relevance of intermediate endpoints for cytotoxic primary systemic therapy

St. Gallen Konsensus 2007 aus deutscher Sicht. Kommentare einer deutschen Arbeitsgruppe zur Therapie des primären Mammakarzinoms

Comprehensive Review on the Surrogate Endpoints of Efficacy Proposed or Hypothesized in the Scientific Community Today

Corrigendum to “A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study”: [Annals of Oncology (2019), volume 30:1279-1288]

Aktive Filter

Suchergebnisse filtern